Inhibrx Biosciences (NASDAQ:INBX - Get Free Report) is anticipated to release its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect Inhibrx Biosciences to post earnings of ($1.6750) per share for the quarter. Interested persons may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Friday, May 15, 2026 at 9:30 AM ET.
Inhibrx Biosciences (NASDAQ:INBX - Get Free Report) last issued its quarterly earnings results on Thursday, March 19th. The company reported ($2.11) EPS for the quarter, missing the consensus estimate of ($2.08) by ($0.03). On average, analysts expect Inhibrx Biosciences to post $-11 EPS for the current fiscal year and $-9 EPS for the next fiscal year.
Inhibrx Biosciences Stock Up 0.1%
Shares of INBX opened at $128.12 on Wednesday. The company has a debt-to-equity ratio of 12.58, a quick ratio of 3.93 and a current ratio of 3.93. Inhibrx Biosciences has a one year low of $10.84 and a one year high of $155.29. The stock has a market capitalization of $1.87 billion, a price-to-earnings ratio of -14.17 and a beta of 3.88. The stock has a 50 day moving average price of $80.33 and a 200 day moving average price of $77.63.
Analyst Ratings Changes
Several brokerages recently commented on INBX. Stifel Nicolaus began coverage on Inhibrx Biosciences in a research report on Wednesday, April 8th. They set a "buy" rating and a $150.00 price target for the company. Wall Street Zen upgraded Inhibrx Biosciences from a "sell" rating to a "hold" rating in a research report on Saturday. Lifesci Capital upgraded Inhibrx Biosciences to a "strong-buy" rating in a research report on Friday, April 24th. Zacks Research raised Inhibrx Biosciences to a "hold" rating in a research note on Thursday, April 9th. Finally, Weiss Ratings reissued a "sell (d)" rating on shares of Inhibrx Biosciences in a research note on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Inhibrx Biosciences presently has a consensus rating of "Hold" and a consensus price target of $150.00.
Check Out Our Latest Report on Inhibrx Biosciences
Hedge Funds Weigh In On Inhibrx Biosciences
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Invesco Ltd. boosted its stake in Inhibrx Biosciences by 539.6% during the fourth quarter. Invesco Ltd. now owns 112,396 shares of the company's stock worth $8,879,000 after buying an additional 94,822 shares during the last quarter. Corient Private Wealth LLC acquired a new position in Inhibrx Biosciences during the fourth quarter worth $1,615,000. XTX Topco Ltd acquired a new position in Inhibrx Biosciences during the fourth quarter worth $713,000. Virtus Investment Advisers LLC acquired a new position in Inhibrx Biosciences during the fourth quarter worth $264,000. Finally, SummitTX Capital L.P. boosted its stake in Inhibrx Biosciences by 53.1% during the fourth quarter. SummitTX Capital L.P. now owns 82,885 shares of the company's stock worth $6,548,000 after buying an additional 28,742 shares during the last quarter. Institutional investors and hedge funds own 82.46% of the company's stock.
Inhibrx Biosciences Company Profile
(
Get Free Report)
Inhibrx, Inc, headquartered in La Jolla, California, is a clinical-stage biotechnology company focused on the discovery and development of next-generation protein therapeutics. The company's proprietary protein engineering platform enables the design and production of multispecific and multivalent biologics with tailored binding characteristics and favorable pharmacokinetic properties. By leveraging high-throughput screening and structure-based design, Inhibrx aims to create molecules that address challenging targets in oncology, regenerative medicine and other areas of unmet medical need.
The company's lead candidate, INBRX-109, is a tetravalent agonist of the receptor tyrosine kinase ROR2 designed to stimulate tissue repair and regeneration.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Inhibrx Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibrx Biosciences wasn't on the list.
While Inhibrx Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
